Aurobindo Pharma submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026, to the Bombay Stock Exchange and National Stock Exchange of India Limited on August 3, 2026. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s environmental, social, and governance performance on a consolidated basis. The report highlights a renewable energy share of 18.4% against a 2030 target of 40%, while disclosing operational footprints across 151 countries and a workforce exceeding 46,000 individuals.

The submission was digitally signed by B. Adi Reddy, Company Secretary and Compliance Officer, on August 3, 2026. The disclosures cover general entity details, material risk assessments, and principle-wise performance indicators aligned with the National Guidelines on Responsible Business Conduct. M/s. Sharp & Tannan Associates provided reasonable assurance on specific identified sustainability information, including energy, water, greenhouse gas emissions, waste management, and employee safety metrics.

Operational and Workforce Overview

Aurobindo Pharma operates 31 manufacturing facilities under commercial operations, alongside 5 international plants and 57 offices globally. The company serves markets in 28 Indian states and union territories, plus 151 countries internationally, with exports contributing 91% of total turnover. The primary business activity involves the development, manufacture, and sale of Active Pharma Ingredients and Formulations, accounting for 100% of turnover.

As of March 31, 2026, the company employed 29,209 permanent employees and engaged 17,246 non-permanent workers. Women constitute 10% of permanent employees and 20% of workers. The Board of Directors includes 11% female representation. The company reported no fines, penalties, or imprisonment proceedings during the fiscal year.

Environmental Performance and Targets

The company consumed 1,70,250 MWh of renewable power in FY26, comprising 50,791 MWh from captive solar plants and 1,19,459 MWh purchased from associate companies. This represents an 18.4% share of total energy consumption. The firm aims to reach a 40% renewable energy share by 2030, with a baseline year of 2025. Additionally, Aurobindo targets a 25% reduction in carbon footprint (Scope 1 and 2) and 70% water conservation/restoration by 2030.

Waste management initiatives achieved 100% reuse or recycling of non-hazardous waste. For hazardous waste, 66% was co-processed, approaching the 2030 target of 70%. The company has achieved Zero Liquid Discharge status at four units: Apitoria Unit-1, Unit-2, Unit-3, and Unit-5. Total Scope 3 emissions were reported at 6,06,351 tCO2e, driven primarily by fuel and energy-related activities (3,64,215 tCO2e) and downstream transportation (1,26,833 tCO2e).

Material Risks and Governance

The report identifies energy management, climate change, and workforce wellbeing as material risks and opportunities. Rising energy costs and stringent regulatory targets pose cost-related risks, while energy efficiency initiatives offer potential savings. The company adheres to policies on Business Ethics, Human Rights, and Supplier Code of Conduct, extending these requirements to value chain partners. Approximately 77% of key starting material suppliers for finished dosage forms in India have been assessed against the Supplier Code of Conduct.

Corporate governance oversight is managed by the ESG and Sustainability Committee, chaired by Dr. M. Madan Mohan Reddy. The Audit Committee reviews internal audit reports covering these principles. The company confirmed compliance with applicable environmental laws and reported no significant adverse impacts from its value chain. CSR applicability is confirmed under Section 135 of the Companies Act, 2013, with a consolidated net worth of INR 37,883 Cr and turnover of INR 33,653 Cr.

Aurobindo Pharma Limited has scheduled its 39th Annual General Meeting (AGM) for Thursday, August 27, 2026, to confirm an interim dividend of ₹4 per equity share for FY26 and seek shareholder approval for the reappointment of two directors. The meeting will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM), with remote e-voting open from August 24 to August 26, 2026. Shareholders must act by the voting deadline to influence governance decisions and approve the appointment of a new Secretarial Auditor.

The primary business includes adopting the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The Board proposes confirming the interim dividend of ₹4 per equity share of ₹1 face value, previously declared for FY25-26. Additionally, shareholders will vote on the reappointment of Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. Both directors hold significant experience in the pharmaceutical sector, with Mr. Reddy serving since 1986 and Dr. Reddy since 2006.

Key Agenda Items

The AGM notice outlines several critical resolutions for shareholder approval:

Mr. K. Nithyananda Reddy, who drew remuneration of ₹54.69 million in FY26, holds 25,359,572 equity shares. Dr. M. Madan Mohan Reddy, who drew ₹69.78 million in FY26, holds 2,010 equity shares. Their reappointments are subject to shareholder approval under Section 152 of the Companies Act, 2013.

New Secretarial Auditor Appointment

The Board has recommended the appointment of M/s. RPR & Associates, Practicing Company Secretaries, as the Secretarial Auditor for a term of five years, from FY27 to FY31. This replaces M/s. MRR & Associates, which resigned on May 21, 2026, due to health issues of its sole proprietor. The initial remuneration for FY27 is proposed at ₹250,000 plus out-of-pocket expenses and applicable taxes. The appointment aligns with Regulation 24A of the SEBI Listing Regulations and Section 204 of the Companies Act, 2013.

Voting and Participation Details

Shareholders holding shares as on the cut-off date of August 20, 2026, are eligible to vote. Remote e-voting commences on Monday, August 24, 2026, at 9:00 a.m. and ends on Wednesday, August 26, 2026, at 5:00 p.m. The Register of Members and Share Transfer Books will remain closed from August 26 to August 27, 2026. Institutional investors must submit board resolutions authorizing representatives to vote via email to the scrutinizer, M/s. RPR & Associates.

What the Numbers Show

The confirmation of the ₹4 interim dividend signals continuity in capital return policy despite broader market volatility. The high remuneration drawn by retiring directors—₹54.69 million and ₹69.78 million respectively—reflects their seniority and long-standing association with the company. The change in Secretarial Auditor is a procedural update following the resignation of the previous firm, ensuring uninterrupted compliance monitoring for complex corporate governance requirements.